ArticleBrain pathology (Zurich, Switzerland)2012
Endothelial expression of endocan is strongly associated with tumor progression in pituitary adenoma.
Article in Brain pathology (Zurich, Switzerland), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Aggressive PitNETs and Potential Target Therapies: A Systematic Review of Molecular and Genetic Pathways.International journal of molecular sciences · 2023Pooled it
- Upregulation of endocan by Epstein-Barr virus latent membrane protein 1 and its clinical significance in nasopharyngeal carcinoma.PloS one · 2013Trial
- Single-cell and spatial transcriptome analyses reveal tumor heterogeneity and immune remodeling involved in pituitary neuroendocrine tumor progression.Nature communications · 2025Article
- Protein Tyrosine Phosphatase Receptors N and N2 Control Pituitary Melanotroph Development and POMC Expression.Endocrinology · 2024Article
- Endocan-microvascular Density in Primary Ovarian Carcinoma.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Overview of omics biomarkers in pituitary neuroendocrine tumors to design future diagnosis and treatment strategies.The EPMA journal · 2021Review
- Targeting Endothelial Cell-Specific Molecule 1 Protein in Cancer: A Promising Therapeutic Approach.Frontiers in oncology · 2021Review
- Cell proliferation, apoptosis, and angiogenesis in non-functional pituitary adenoma: association with tumor invasiveness.Endocrine · 2020Article
- Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours.Endocrine · 2020Article
- Prediction and identification of novel HLA-A*0201-restricted cytotoxic T lymphocyte epitopes from endocan.Journal of inflammation (London, England) · 2020Article
- Identification of key genes in invasive clinically non-functioning pituitary adenoma by integrating analysis of DNA methylation and mRNA expression profiles.Journal of translational medicine · 2019Article
- Endothelial cell-specific molecule-1 as an invasiveness marker for pituitary null cell adenoma.BMC endocrine disorders · 2019Article
- Identification of ESM1 overexpressed in head and neck squamous cell carcinoma.Cancer cell international · 2019Article
- Review
- Sex-Related Differences in Lactotroph Tumor Aggressiveness Are Associated With a Specific Gene-Expression Signature and Genome Instability.Frontiers in endocrinology · 2018Article
- Plasma Levels of Endothelial Cell-Specific Molecule-1 as a Potential Biomarker of Oral Cancer Progression.International journal of medical sciences · 2017Article
- Endocan reduces the malign grade of gastric cancer cells by regulating associated protein expression.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Endocan-expressing microvessel density as a prognostic factor for survival in human gastric cancer.World journal of gastroenterology · 2016Observational
- Clinical Impact of the Current WHO Classification of Pituitary Adenomas.Endocrine pathology · 2016Review
- Dopamine agonist resistance-related endocan promotes angiogenesis and cells viability of prolactinomas.Endocrine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although benign, pituitary adenomas frequently invade adjacent sinuses or recur after first surgery. To date, there is no histological marker predictive of recurrence. Angiogenic factors are candidate markers. Endocan is a proteoglycan secreted by endothelial cells, associated with an aggressive behavior in several tumor types. Endocan expression was investigated by immunohistochemistry and reverse transcription polymerase chain reaction (RT-PCR) in 18 normal post-mortem pituitaries and in 107 patients operated for a pituitary adenoma (with a follow-up of at least 8 years after surgery). In normal pituitaries, endocan was never observed in vessels but was detected in isolated endocrine cells. In adenoma tissue, we found a strong association between endocan immunoreactivity in endothelial cells and progression (P = 0.0009), as well as tumor size (P = 0.0012), raised mitotic count (P = 0.02) and p53 expression (P = 0.032). Morphometric analysis of the microvessels showed that the mean vessel area was significantly higher in the subgroup of tumors with an endothelial expression of endocan (P = 0.028), coherent with the neoangiogenesis process occurring in the pituitary. The immunolabeling of endocan in endothelial cells may therefore appear to be a relevant marker of aggressive behavior in pituitary tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.